Virological response and resistance profile in HIV-1 infected patients

Virological response and resistance profile were evaluated in drug-naïve patients starting their first-line integrase inhibitors (INIs)-based regimen in a clinical setting. Virological success (VS) and virological rebound (VR) after therapy start were assessed by survival analyses. Drug-resistance was evaluated at baseline and at virological failure. The study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo). HC+AZ, HC, and placebo groups had 6 (3·9%), 7 (4·6%), and 9 (5·9%) participants go off study medications before completing the medication course (p = 0·716). Day six PCR results were available for all 152 HC+AZ participants, 149/152 (98·0%) HC participants, and 147/152 (96·7%) placebo participants. Day six ITT analysis found no difference (p = 0·821) in groups’ proportions achieving virologic cure: HC+AZ 16/152 (10·5%), HC 19/149 (12·8%), placebo 18/147 (12·2%). Day 14 assessment also showed no association (p = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events. HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19.

A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.scholarscentral.org/submissions/asian-biomedical-pharmaceutical-sciences.html) or forwarded to the Editorial Office at  jbiopharm@scholarlypub.com.

Media Contact:  

Alina Grace            

Journal Manager

Asian Journal of Biomedical & Pharmaceutical Sciences

Email: jbiopharm@scholarlypub.com